Telomerase is expressed in most types of tumors but not in most somatic cells. This observation has led to two hypotheses; (i) telomerase activity is necessary for the proliferation of cancer cells; and (ii) telomerase inhibitors are a powerful strategy for cancer chemotherapy. Testing the latter hypothesis requires the development of potent and selective inhibitors of telomerase and their testing in clinical trials. Assaying the ecacy of telomerase inhibitors will not be simple because telomere erosion will be slow and antiproliferative eects will probably require weeks to become apparent. This review will describe the properties of 2'-O-alkyl oligonucleotide inhibitors of telomerase. Oligonucleotides that block expression of other cancer targets have favorable pharmacokinetic properties and are already in clinical trials. This experience is likely to facilitate clinical trials of anti-telomerase oligomers.
Introduction
Telomerase activity is expressed in cancer cells but not in most normal somatic cells, suggesting that telomerase may be an important target for chemotherapy (Kim et al., 1994; Counter et al., 1994; Bearss et al., 2000) . This review will describe the advantages of 2'-O-alkyl oligonucleotides as telomerase inhibitors. Oligonucleotides directed at other oncology targets are being administered to patients to treat cancer (Crooke, 2000) , providing clinical experience that is likely to facilitate the initiation of human trials of anti-telomerase therapy.
Telomerase inhibition
In contrast to traditional antiproliferative agents that kill cells within hours or days after administration, telomerase inhibitors are likely to require weeks before eects become apparent (Figure 1 ). This lag phase will vary with telomere length and occurs because telomeres in human tumor cells are hundreds or thousands of bases long and erode at a rate of 50 to 100 bases per population doubling (Hastie et al., 1990; Harley et al., 1990) . Delayed observation of phenotype has been observed in knockout mice (Blasco et al., 1997; Liu et al., 2000) , cell lines that express dominant negative hTERT (Zhang et al., 1999; Hahn et al., 1999) and upon application of oligonucleotide inhibitors (see below) (Herbert et al., 1999 (Herbert et al., , 2001 Shammas et al., 1999) .
The lag period might be relatively brief if one or more telomeres are critically short prior to the start of treatment. Alternatively, telomere shortening may make cells more sensitive to other chemotherapy agents. von Zglinicki and co-workers have recently reported that inhibition of telomerase activity by expression of a ribozyme targeted against hTERT increases the sensitivity of breast cancer cells to doxorubicin, a topoisomerase inhibitor (Ludwig et al., 2001) . However, even if the lag phase can be reduced it is likely that anti-telomerase therapy will require weeks. As a result, an anti-telomerase drug will need to be potent, nontoxic, and act synergistically with existing therapeutics.
Telomerase as a target for oligonucleotides
Telomerase consists of an RNA component (hTR) that acts to bind the telomere (Feng et al., 1995) and a protein component (hTERT) that acts as a reverse transcriptase (Meyerson et al., 1997 , Harrington et al., 1997 Nakamura et al., 1997) . Targeting the RNA template region of the RNA with oligonucleotides oers several advantages for inhibitor development. (i) For telomerase to function, hTR must be able to Watson-Crick basepair with the telomere. This accessibility makes hTR ideal target for oligonucleotides. (ii) The design of oligonucleotide-based inhibitors is simple because the sequence of the 11 base hTR template region is known. (iii) Obtaining oligomers with unique chemical properties for testing is straightforward. Many dierent types of oligonucleotides are commercially available or can be readily synthesized, each possessing unique chemical properties (Table 1, Figure  2 ). (iv) Control experiments can use oligonucleotides that contain mismatched bases. Such controls oer a proof of mechanism that is dicult to achieve otherwise.
In the ®rst report of inhibition of telomerase by oligomers the telomerase template was targeted with peptide nucleic acids (PNAs) (Norton et al., 1996) (Figure 2 ), a DNA mimic with a neutral amide backbone. Complementary PNAs inhibited telomerase in cell extract with IC 50 values as low as 1 nM while mismatch-containing PNAs were inactive. Subsequent studies using PNAs revealed that recognition of cytidines 50 ± 52 within the template region was critical for ecient inhibition (Hamilton et al., 1997) . PNAs directed to other sites within hTR were poor inhibitors of telomerase holoenzyme .
These initial results were encouraging because they con®rmed that the hTR template was a good target for inhibition by oligonucleotides. PNAs, however, are not well distributed in vivo (Rusckowski et al., 1997) . For a PNA-based anti-telomerase therapeutic to succeed, the pharmocokinetics and toxicology of PNA would need to be optimized in tandem with surmounting the considerable challenges presented by telomerase as a target. Achieving this outcome in the near term appeared unlikely, so further investigations (Pitts and Corey, 1998; Herbert et al., 1999; Elayadi et al., 2001) focused on oligonucleotide chemistries that were already characterized in animals and in human clinical trials.
Clinical experience with oligonucleotides
The use of oligonucleotides for therapy has attracted substantial attention (Lebedeva and Stein, 2001) . One oligonucleotide, Fomivirsen, has been approved as a drug for the treatment of CMV retinitis and is administered by intraocular injection (Marwick, 1998 ; Figure 1 Period between the initiation of treatment and observation of phenotype. Addition of traditional antiproliferative agents to cells causes rapid cell death. Addition of telomerase inhibitors may cause cell proliferation to slow but this eect will depend on initial telomere length . Other oligonucleotides are in clinical trials and are administered systemically by intravenous injection. Several of these drugs are designed to aect tumor proliferation (Table 2) and preliminary studies report favorable responses in patients. Genasense, which is being developed by Genta and targets Bcl-2, has shown encouraging signs of ecacy in trials against a variety of cancer types (Banerjee, 2001) . Another oligomer, ISIS 3521, is being developed by ISIS Pharmaceuticals in collaboration with Eli Lilly Pharmaceuticals to target protein kinase C-a and has demonstrated favorable results in a Phase I/II trial against non-small cell lung cancer (Yuen et al., 2001) . Experience with oligonucleotides in the clinic facilitates their development as telomerase inhibitors (Table  3) . Methods for large-scale synthesis have been developed, and oligonucleotides can be produced for as little as $200 per gram when made on a multikilogram scale. The pharmacokinetic properties of oligonucleotides are well characterized and toxicity is low (Geary et al., 2001) . There are even some indications that adequate oral bio-availability can be obtained (Khatsenko et al., 2000) .
Perhaps most importantly, clinical data indicating a favorable impact on tumor progression suggests that oligonucleotides can enter human tumors and ®nd their targets (Banerjee, 2001; Yuen et al., 2001) . Since chemically similar oligonucleotides appear to share pharmacokinetic properties regardless of the target that they are directed to (Geary et al., 2001) , it is reasonable to expect that anti-telomerase oligomers will be able to enter tumors in patients. Because the telomerase template is exceptionally accessible to binding by oligonucleotides, anti-telomerase oligomers may be even more potent than the mRNA-targeted antisense agents now in trials.
Design of therapeutic oligonucleotides
To understand the design of oligonucleotides that target hTR, it is useful to understand the considerations that apply to the design of antisense oligomers in general (Table 3) . Typical antisense oligonucleotides contain DNA bases that can form DNA ± RNA hybrids upon binding to mRNA. RNase H recognizes these hybrids, cleaves them, and the destruction of mRNA reduces protein expression (Baker and Monia, 1999) . Telomerase is not a typical antisense target because cleavage of hTR by RNase H is not necessary.
It is sucient for oligonucleotides to bind to hTR and act as competitive inhibitors at the active site (Norton et al., 1996) , making their mode of action similar to that of traditional enzyme inhibitors.
Because RNase H cleavage is not necessary for telomerase inhibition, there is no need to include DNA bases in anti-telomerase oligonucleotides. This allows them to be entirely composed of chemically modi®ed bases that bind complementary sequences with elevated anity, such as PNA (Norton et al., 1996; Herbert et al., 1999) , 2'-O-alkyl RNA (Herbert et al., 1999; Elayadi et al., 2001) , or locked nucleic acid (LNA) (Braasch and Corey, 2001) ( Figure 2) . In contrast to antisense oligonucleotides, which are normally 18 to 25 bases long, high anity binding by modi®ed bases allows anti-telomerase oligomers to be as short as eight to 13 bases, cutting synthesis costs.
Another important consideration in the design of therapeutic antisense oligonucleotides is the presence of phosphorothioate (PS) linkages between the bases (Levin, 1999) (Figures 2 and 3) . PS linkages were ®rst introduced into DNA to enhance stability against nuclease digestion. Later, PS linkages were found to enhance binding to proteins. Such interactions can cause phenotypes that are unrelated to binding to the target mRNA and confound the interpretation of results (Lebedeva and Stein, 2001) . If an oligonucleotide causes cells to die, is the phenotype due to downregulation of the target activity or an unintended interaction between its PS-modi®ed backbone and an irrelevant transcription factor or cell surface protein?
To resolve such questions it is essential to use mismatch-containing oligonucleotides as controls before suggesting that the observed phenotype is due to hybridization to the target RNA. It is worth noting that 20-base oligonucleotides containing PS substitutions inhibit telomerase in cell extract regardless of sequence (Norton et al., 1996; Matthes and Lehmann, 1999; Elayadi et al., 2001) , presumably through interactions between the thioate linkage and hTERT.
We have observed, however, that inhibition by 20-base PS-oligomers is sequence-speci®c when measured inside cells (Elayadi et al., 2001) . Presumably, the interactions between PS-modi®ed oligonucleotides and hTERT are relatively weak and are easily dissociated within the complex and crowded cellular environment. The low level of toxicity in humans observed during clinical suggests that nonselective interactions are well-tolerated in vivo. The other, much more favorable, consequence of the association of oligonucleotides with proteins is that the serum half-life of PS-oligonucleotides is greatly increased (Geary et al., 2001) . It may be possible to maintain eective in vivo concentrations with only three or four injections per month. Because PS linkages aord an improvement in pharmacokinetic properties, it is likely that they will need to be incorporated into any therapeutic anti-telomerase oligonucleotide.
A ®nal consideration is whether the nucleobase or ribose moieties are chemically modi®ed. Modi®cation of the 2' hydroxyl of RNA increases binding anity (Freier and Altmann, 1997) . Tighter binding increases the ability of oligonucleotides to potently recognize complementary sequences. 2'-O-methyl and 2'-methoxyethyl modi®ed RNA are currently being employed in clinical trials and exhibit improved ecacy and pharmacological properties (Henry et al., 2000; Khatsenko et al., 2000; Baker et al., 1997) .
Inhibition of telomerase by 2'-O-alkyl RNA
Use of 2'-O-alkyl RNA in clinical trials suggested that they should be tested as telomerase inhibitors. Thirteen base oligonucleotides that are complementary to the hTR template and are composed of either 2'-O-methyl RNA (Pitts and Corey, 1998; Herbert et al., 1999 Herbert et al., , 2001 or 2'-methoxyethyl RNA (Elayadi et al., 2001) are potent telomerase inhibitors, with IC 50 values in cell lysate of approximately 10 nM. Similar oligonucleotides that contain mismatched bases inhibit 41000fold less well. When PS linkages are introduced, IC 50 values of fully complementary oligonucleotides are 3 ± 10 nM. Mismatch containing PS oligomers inhibit approximately 300-fold less well. Thus, anti-telomerase oligomers containing 2'-O-alkyl RNA combine potent and selective inhibition with the PS linkages needed for good pharmacokinetic properties. Twenty-base anti-telomerase PS-substituted 2'-methoxyethyl oligonucleotides are also potent inhibitors, with IC 50 values of approximately 1 nM (Elayadi et al., 2001) . This is a signi®cant ®nding because the oligonucleotides currently used in clinical trials are 20 bases long and contain similar chemical modi®cations. This experience with chemically closely related oligonucleotides may confer important practical advantages for initiating clinical trials of anti-telomerase therapy with these relatively long oligonucleotides rather than their shorter 13-base analogs.
Inhibition of cellular telomerase by oligonucleotides
Thirteen-base 2'-O-meRNA oligomers were introduced into three cultured immortal cell lines, HME50-5E, HME50-5E-hTERT, and DU145, to examine their eects on cell proliferation (Herbert et al., 1999) . Breast epithelial cell line HME50-5E has very short telomeres. Derivative cell line HME50-5E hTERT has been transfected with hTERT and has long (12 kB) telomeres. Comparing the eects of telomerase inhibition in HME50-5E and HME50-hTERT allows the eects of inhibition to be compared in matched cell lines that are similar but dier in telomere length. Inhibition was also examined in DU145 cells, a prostate cancer line with intermediate length telomeres.
For each of the three cell lines tested, cells that were treated with fully complementary oligonucleotide showed telomere shortening over time, while mismatch-containing oligonucleotides caused no erosion (Figure 4) . Once treatment was concluded, telomeres returned to their initial lengths. This latter result emphasizes and suggests that once started, anti-telomerase therapy will need to be maintained without pause until the course of treatment is complete.
None of the cell lines showed immediate antiproliferative eects when treated with match oligonucleotide ( Figure 5 ). HME50-5E cells that were treated with complementary oligonucleotide began to grow slowly after 30 days and stopped proliferating after 110 days. Proliferation of DU145 cells slowed, but never stopped, while proliferation of HME50hTERT cells continued without pause. These results demonstrate that inhibition of telomerase by synthetic inhibitors can reduce the proliferation of immortal cells, but that the antiproliferative eect is critically dependent on telomere length. Similar results have been observed for cells treated with PNAs (Shammas et al., 1999) . The 13-base 2'-O-meRNA oligomer has also been shown to act as a chemopreventative agent to prevent the spontaneous immortalization of epithelial cells (Herbert et al., 2001) .
When evaluating these results, it is important to understand that the need to introduce oligonucleotide by repeatedly transfecting cells with cationic lipid slows their doubling rate, extending the time required before eects are observed. Also, these experiments use antitelomerase agents as a single agent in cell culture. It is possible that single agent or combination treatments in animals might produce more rapid results. Telomerase inhibition and moderate telomere shortening may weaken cells and make them more susceptible to other antiproliferative agents or to attack by the immune system. 
How clinical trials might unfold
Anti-telomerase oligonucleotides are eective antiproliferative agents and belong to a class of molecule that shows low toxicity and encouraging pharmocokinetics when administered in humans. These facts encourage the belief that a clinical test of the connection between telomerase inhibition and cancer therapy may be possible in the near future ( Figure 6 ). However, before clinical trials can be initiated, preclinical trials will be needed to examine whether the administration of oligonucleotides is toxic to stem cells. It will also be useful to study the eect of telomerase inhibition on telomere size and growth of human xenograft tumors.
The design of these trials must recognize that antitelomerase inhibitors are unlikely to produce the acute anti-proliferative eects needed to be a useful primary therapy. Rather, telomerase inhibitors will be used after initial chemotherapy, surgery, or radiation had removed the bulk of the tumor. Inhibitors of telomerase will then be administered as an adjuvant therapy in conjunction with standard therapeutic regimes. Telomere length will be a critical consideration, and it may be necessary to screen for patients whose tumors are characterized by relatively short telomeres.
Biochemical markers for ecacy include observation of telomerase inhibition and demonstration of telomere shortening. A reasonable endpoint for studies would be prolonging the average time of tumor recurrence. It is obvious that anti-telomerase therapy would greatly bene®t from shortening the time between initiation of treatment and observation of positive eects. An important challenge for basic and preclinical work will be to suggest combination therapies to best exploit the erosion of telomeres and possibly cause a more rapid decrease on cell proliferation.
Conclusion
The arguments for and against telomerase as a target for chemotherapy can only be resolved by use of eective inhibitors in human trials, making the design and implementation of such trials a priority for workers in the ®eld. 2'-methoxyethyl RNA inhibitors of telomerase oer substantial advantages for clinical trial design. 2'-methoxyethyl RNA is relatively nontoxic in humans, its scale up synthesis has been Herbert et al. (1999) developed, partial oral bioavailability can be achieved, and similar oligomers appear to be producing favorable outcomes in patients in clinical trials.
In the long run, traditional small molecule approaches to inhibitor design or the phosphoramidate oligonucleotides described elsewhere in this issue may produce superior anti-telomerase drugs. However, given that the lag phase between initiation of treatment and observation of phenotype complicates clinical trial design, the use of 2'-methoxyethyl RNA may provide the most rapid route to the clinic. Not only might such trials produce a useful new drug for treating cancer, but they are likely to also aord important lessons for other approaches to anti-telomerase therapy that employ classes of agent that are less well characterized.
